Effects of quercetin supplementation on lipid profile: A systematic review and meta-analysis of randomized controlled trials

References

• Askari, G., Ghiasvand, R., Feizi, A., Ghanadian, S. M. and Karimian, J. (2012). The effect of quercetin supplementation on selected markers of inflammation and oxidative stress. J. Res. Med. Sci. 17:637–641.
   PubMed Web of Science ®Google Scholar
• Assmann, G. (2006). Dyslipidaemia and global cardiovascular risk: Clinical issues. Eur. Heart J. Suppl. 8:F40–F46.
   Web of Science ®Google Scholar
• Banach, M., Serban, C., Aronow, W. S., Rysz, J., Dragan, S., et al. (2014). Lipid, blood pressure and kidney update 2013. Int. Urol. Nephrol. 6:947–961.
   Web of Science ®Google Scholar
• Bhaskar, S., Kumar, K. S., Krishnan, K. and Antony, H. (2013). Quercetin alleviates hypercholesterolemic diet induced inflammation during progression and regression of atherosclerosis in rabbits. Nutrition 29:219–229.
   PubMed Web of Science ®Google Scholar
• Boots, A. W., Haenen, G. R. M. M. and Bast, A. (2008). Health effects of quercetin: From antioxidant to nutraceutical. Eur. J. Pharmacol. 585:325–337.
   PubMed Web of Science ®Google Scholar
• Borenstein, M., Hedges, L., Higgins, J. and Rothstein, H. (2005). Comprehensive Meta-analysis Version 2. Biostat, Englewood NJ.
   Google Scholar
• Casaschi, A., Wang, Q., Dang, K., Richards, A. and Theriault, A. (2002). Intestinal apolipoprotein B secretion is inhibited by the flavonoid quercetin: Potential role of microsomal triglyceride transfer protein and diacylglycerol acyltransferase. Lipids 37:647–652.
   PubMed Web of Science ®Google Scholar
• Castilla, P., Echarri, R., Dávalos, A., Cerrato, F., Ortega, H., et al. (2006). Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am. J. Clin. Nutr. 84:252–262.
   PubMed Web of Science ®Google Scholar
• Chopra, M., Fitzsimons, P. E., Strain, J. J., Thurnham, D. I. and Howard, A. N. (2000). Nonalcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations. Clin. Chem. 46:1162–1170.
   PubMed Web of Science ®Google Scholar
• Conquer, J. A., Maiani, G., Azzini, E., Raguzzini, A. and Holub, B. J. (1998). Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J. Nutr. 128:593–597.
   PubMed Web of Science ®Google Scholar
• Duval, S. and Tweedie, R. (2000). Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463.
   PubMed Web of Science ®Google Scholar
• Edwards, R. L., Lyon, T., Litwin, S. E., Rabovski, A., Symons, J. D. and Jalili, T. (2007). Quercetin reduces blood pressure in hypertensive subjects. J. Nutr. 137:2405–2411.
   PubMed Web of Science ®Google Scholar
• Egert, S., Boesch-Saadatmandi, C., Wolffram, S., Rimbach, G. and Müller, M. J. (2010). Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J. Nutr. 140:278–284.
   PubMed Web of Science ®Google Scholar
• Egert, S., Bosy-Westphal, A., Seiberl, J., et al. (2009). Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: A double-blinded, placebo-controlled cross-over study. Br. J. Nutr. 102:1065–1074.
   PubMed Web of Science ®Google Scholar
• Egert, S., Wolffram, S., Bosy-Westphal, A., Kürbitz, C., Settler, U. et al. (2008). Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J. Nutr. 138:1615–1621.
   PubMed Web of Science ®Google Scholar
• Falcone Ferreyra, M. L., Rius, S. P. and Casati, P. (2012). Flavonoids: Biosynthesis, biological functions, and biotechnological applications. Front. Plant Sci. 3:222.
   PubMed Web of Science ®Google Scholar
• Ferrer, J., Austin, M., Stewart, C. J. and Noel, J. (2008). Structure and function of enzymes involved in the biosynthesis of phenylpropanoids. Plant Physiol. Biochem. 46:356–370.
   PubMed Web of Science ®Google Scholar
• Ferretti, G., Bacchetti, T. and Sahebkar, A. (2015). Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials (2015) Prog. Lipid Res. 60:50–73.
   PubMed Web of Science ®Google Scholar
• Gee, J. M., DuPont, M. S., Day, A. J., Plumb, G. W., Williamson, G. and Johnson, I. T. (2000). Intestinal transport of quercetin glycosides in rats involves both deglycosylation and interaction with the hexose transport pathway. J. Nutr. 130:S2765–S2771.
   PubMed Web of Science ®Google Scholar
• Geleijnse, J. M., Launer, L. J., Van der Kuip, D. A., Hofman, A. and Witteman, J. C. (2002). Inverse association of tea and flavonoid intakes with incident myocardial infarction: The Rotterdam Study. Am. J. Clin. Nutr. 75:880–886.
   PubMed Web of Science ®Google Scholar
• Ghorbani, A. (2013). Phytotherapy for diabetic dyslipidemia: Evidence from clinical trials. Clin. Lipidol. 8:311–319.
   Web of Science ®Google Scholar
• Glässer, G., Graefe, E. U., Struck, F., Veit, M. and Gebhardt, R. (2002). Comparison of antioxidative capacities and inhibitory effects on cholesterol biosynthesis of quercetin and potential metabolites. Phytomedicine 9:33–40.
   PubMed Web of Science ®Google Scholar
• Gnoni, G. V., Paglialonga, G. and Siculella, L. (2009). Quercetin inhibits fatty acid and triacylglycerol synthesis in rat-liver cells. Eur. J. Clin. Invest. 39:761–768.
   PubMed Web of Science ®Google Scholar
• Golomb, B. A. and Evans, M. A. (2008). Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. Am. J. Cardiovasc. Drugs 8:373–418.
   PubMed Web of Science ®Google Scholar
• Graefe, E. U., Derendorf, H. and Veit, M. (1999). Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int. J. Clin. Pharmacol. Ther. 37:219–233.
   PubMed Web of Science ®Google Scholar
• Harper, C. R. and Jacobson, T. A. (2007). The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis. Curr. Opin. Lipidol. 18:401–408.
   PubMed Web of Science ®Google Scholar
• Higgins, J. P. T., Green, S., editors. (2009). Cochrane handbook for systematic reviews of interventions Version 5.0.2. The Cochrane Collboration.
   Google Scholar
• Hollman, P. C. H. and Katan, M. B. (1999). Dietary Flavonoid: Intake, health effects and bioavailability. Food Chem. Toxicol. 37:937–942.
   PubMed Web of Science ®Google Scholar
• Hooper, L., Kroon, P. A., Rimm, E. B., Cohn, J. S., Harvey, I., et al. (2008). Flavonoids, flavonoid-rich foods, and cardiovascular risk: A meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 88:38–50.
   PubMed Web of Science ®Google Scholar
• Hubbard, G. P., Stevens, J. M., Cicmil, M., et al. (2003). Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J. Thromb. Haemost. 1:1079–1088.
   PubMed Web of Science ®Google Scholar
• Hwang, E. K. (2009). Effect of quercetin supplement on major biochemical parameters in sera of rats fed high fat and high cholesterol diet. J. Veterinary Clin. 26:413–418.
   Google Scholar
• Hämäläinen, M., Nieminen, R., Vuorela, P., Heinonen, M. and Moilanen, E. (2007). Anti-inflammatory effects of flavonoids: Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm. 2007:45673.
   PubMed Web of Science ®Google Scholar
• Igarashi, K. and Ohmuma, M. (1995). Effects of isorhamnetin, rhamnetin, and quercetin on the concentrations of cholesterol and lipoperoxide in the serum and liver and on the blood and liver antioxidative enzyme activities of rats. Biosci. Biotechnol. Biochem. 59:595–601.
   PubMed Web of Science ®Google Scholar
• Juźwiak, S., Wójcicki, J., Mokrzycki, K., Marchlewicz, M., Białecka, M., et al. (2005). Effect of quercetin on experimental hyperlipidemia and atherosclerosis in rabbits. Pharmacol. Rep. 57:604–609.
   PubMed Web of Science ®Google Scholar
• Kalogeromitros, D., Makris, M., Chliva, C., Aggelides, X., Kempuraj, D. and Theoharides, T. C. (2008). A quercetin containing supplement reduces niacin-induced flush in humans. Int. J. Immunopathol. Pharmacol. 21:509–514.
   PubMed Web of Science ®Google Scholar
• Kamada, C., da Silva, E. L., Ohnishi-Kameyama, M., Moon, J. H. and Terao, J. (2005). Attenuation of lipid peroxidation and hyperlipidemia by quercetin glucoside in the aorta of high cholesterol-fed rabbit. Free Radic. Res. 39:185–194.
   PubMed Web of Science ®Google Scholar
• Kelly, G. S. (2011). Quercetin. Altern. Med. Rev. 16:172–194.
   PubMedGoogle Scholar
• Kelly, G. S. (2011). Quercetin. Monograph. Altern. Med. Rev. 16:172–194.
   PubMedGoogle Scholar
• Kleemann, R., Verschuren, L., Morrison, M., et al. (2011). Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 218:44–52.
   PubMed Web of Science ®Google Scholar
• Knab, A. M., Shanely, R. A., Henson, D. A., Jin, F., Heinz, S. A., et al. (2011). Influence of quercetin supplementation on disease risk factors in community-dwelling adults. J. Am. Diet Assoc. 111:542–549.
   PubMed Web of Science ®Google Scholar
• Knekt, P., Jarvinen, R., Reunanen, A. and Maatela, J. (1996). Flavonoid intake and coronary mortality in Finland: A cohort study. BMJ 312:478–481.
   PubMed Web of Science ®Google Scholar
• Knekt, P., Kumpulainen, J., Järvinen, R., Rissanen, H., Heliövaara, M., et al. (2002). Flavonoid intake and risk of chronic diseases. Am. J. Clin. Nutr. 76:560–568.
   PubMed Web of Science ®Google Scholar
• Lakhanpal, P. and Kumar, D. (2007). Quercetin: A Versatile Flavonoid. Internet J. Med. Update 2:22–37.
   Google Scholar
• Lamson, D. W. and Brignall, M. S. (2000). Antioxidants and cancer III: Quercetin. Altern. Med. Rev. 5:196–208.
   PubMedGoogle Scholar
• Larson, A. J., Symons, J. D. and Jalili, T. (2012). Therapeutic potential of quercetin to decrease blood pressure: Review of efficacy and mechanisms. Adv. Nutr. 3:39–46.
   PubMed Web of Science ®Google Scholar
• Lee, K. H., Park, E., Lee, H. J., Kim, M. O., Cha, Y. J., et al. (2011). Effects of daily quercetin-rich supplementation on cardiometabolic risks in male smokers. Nutr. Res. Pract. 5:28–33.
   PubMed Web of Science ®Google Scholar
• Loke, W. M., Hodgson, J. M., Proudfoot, J. M., McKinley, A. J., Puddey, I. B. and Croft, K. D. (2008). Pure dietary flavonoids quercetin and (−)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am. J. Clin. Nutr. 88:1018–1025.
   PubMed Web of Science ®Google Scholar
• Mariee, A. D., Abd-Allah, G. M. and El-Beshbishy, H. A. (2012). Protective effect of dietary flavonoid quercetin against lipemic-oxidative hepatic injury in hypercholesterolemic rats. Pharm. Biol. 50:1019–1025.
   PubMed Web of Science ®Google Scholar
• Michalska, M., Gluba, A., Mikhailidis, D. P., et al. (2010). The role of polyphenols in cardiovascular disease. Med. Sci. Monit. 16:RA110–RA119.
   PubMed Web of Science ®Google Scholar
• Michalska-Kasiczak, M., Sahebkar, A., Mikhailidis, D. P., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Kees Hovingh, G., Farnier, M., Moriarty, P. M., Bittner, V. A., Lip, G. Y. H. and Banach, M. (2015). Analysis of vitamin D levels in patients with and without statin-associated myalgia - A systematic review and meta-analysis of 7 studies with 2420 patients. Int. J. Cardiol. 178:111–116.
   PubMed Web of Science ®Google Scholar
• Mohammadi, A., Sahebkar, A., Iranshahi, M., et al. (2013). Effects of supplementation with curcuminoids on dyslipidemia in obese patients: A randomized crossover trial. Phytother. Res. 27:374–379.
   PubMed Web of Science ®Google Scholar
• Moher, D., Liberati, A., Tetzlaff, J. and Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 339:b2535.
   PubMed Web of Science ®Google Scholar
• Nickel, T., Hanssen, H., Sisic, Z., et al. (2011). Immunoregulatory effects of the flavonol quercetin in vitro and in vivo. Eur. J. Nutr. 50:163–172.
   PubMed Web of Science ®Google Scholar
• Nutrient Data Laboratory, Food Composition Laboratory. (2007). USDA database for the flavonoid content of selected foods. Beltsville Human Nutrition Research Center, Agriculture Research Service, USDA, Beltsville, MD.
   Google Scholar
• Pérez-Vizcaíno, F., Ibarra, M., Cogolludo, A. L., et al. (2002). Endothelium-independent vasodilator effects of the flavonoid quercetin and its methylated metabolites in rat conductance and resistance arteries. J. Pharmacol. Exp. Ther. 302:66–72.
   PubMed Web of Science ®Google Scholar
• Pfeuffer, M., Auinger, A., Bley, U., et al. (2013). Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. Nutr. Metab. Cardiovasc. Dis. 23:403–409.
   PubMed Web of Science ®Google Scholar
• Rizzo, M., Barylski, M., Rizvi, A. A., Montalto, G., Mikhailidis, D. P. and Banach, M. (2013). Combined dyslipidemia: Should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr. Pharm. Des. 19:3858–3868.
   PubMed Web of Science ®Google Scholar
• Rock, W., Rosenblat, M., Borochov-Neori, H., Volkova, N., Judeinstein, S. et al. (2009). Effects of date (Phoenix dactylifera L., Medjool or Hallawi Variety) consumption by healthy subjects on serum glucose and lipid levels and on serum oxidative status: A pilot study. J. Agric. Food Chem. 57:8010–8017.
   PubMed Web of Science ®Google Scholar
• Romero, M., Jiménez, R., Sánchez, M., et al. (2009). Quercetin inhibits vascular superoxide production induced by endothelin-1: Role of NADPH oxidase, uncoupled eNOS and PK. C. Atherosclerosis 202:58–67.
   PubMed Web of Science ®Google Scholar
• Russo, M., Spagnuolo, C., Tedesco, I., Bilotto, S. and Russo, G. L. (2012). The flavonoid quercetin in disease prevention and therapy: Facts and fancies. Biochem. Pharmacol. 83:6–15.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A. (2013). Does PPARγ(2) Gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a Meta-Analysis. DNA Cell Biol. 32:188–198.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A. (2013). Fat lowers fat: Purified phospholipids as emerging therapies for dyslipidemia. Biochim. Biophys. Acta. 1831:887–893.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A. (2013). Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 39:197–208.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A. (2014). Curcuminoids for the management of hypertriglyceridaemia. Nat. Rev. Cardiol. 11:123.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A., Chew, G. T. and Watts, G. F. (2014). New peroxisome proliferator-activated receptor agonists: Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin. Pharmacother. 15:493–503.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A., Chew, G. and Watts, G. (2014). Recent advances in pharmacotherapy for hypertriglyceridemia. Progress in Lipids Research. 56:47–66.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A. and Watts, G. F. (2013). New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin. Ther. 35:1082–1098.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A. and Watts, G. F. (2014). Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: Tale of a roller-coaster. Diabetes Obes. Metabol. 16:780–792.
   Web of Science ®Google Scholar
• Sahebkar, A. and Watts, G. F. (2013). New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: What can the clinician expect? Cardiovasc. Drugs Ther. 27:559–567.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A. and Watts, G. F. (2014). Managing recalcitrant hypercholesterolemia in patients on current best standard of care: Efficacy and safety of novel pharmacotherapies. Clin. Lipidol. 9:221–233.
   Web of Science ®Google Scholar
• Sanchez, M., Lodi, F., Vera, R., et al. (2007). Quercetin and isorhamnetin prevent endothelial dysfunction, superoxide production, and overexpression of p47phox induced by angiotensin II in rat aorta. J. Nutr. 137:910–915.
   PubMed Web of Science ®Google Scholar
• Shanely, R. A., Knab, A. M., Nieman, D. C., Jin, F., McAnulty, S. R. and Landram, M. J. (2010). Quercetin supplementation does not alter antioxidant status in humans. Free Radic. Res. 44:224–231.
   PubMed Web of Science ®Google Scholar
• Talirevic, E. and Jelena, S. (2012). Quercetin in the treatment of dyslipidemia. Med. Arh. 66:87–88.
   PubMedGoogle Scholar
• Vita, J. A. (2005). Polyphenols and cardiovascular disease: Effects on endothelial and platelet function. Am. J. Clin. Nutr. 81:292S–297S.
   PubMed Web of Science ®Google Scholar
• Winkel-Shirley, B. (2001). Flavonoid biosynthesis. a colorful model for genetics, biochemistry, cell biology, and biotechnology. Plant Physiol. 126:485–493.
   PubMed Web of Science ®Google Scholar
• Yan, A. T., Yan, R. T., Tan, M., et al. (2006). Contemporary management of dyslipidemia in high-risk patients: Targets still not met. Am. J. Med. 19:676–683.
   Web of Science ®Google Scholar
• Ying, H. Z., Liu, Y. H., Yu, B., Wang, Z. Y., Zang, J. N. and Yu, C. H. (2013). Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils. Food Chem. Toxicol. 52:53–60.
   PubMed Web of Science ®Google Scholar
• Zahedi, M., Ghiasvand, R., Feizi, A. and Asgari, G. R. (2013). Effects of quercetin supplementation on cardiovascular risk factors and inflammatory biomarkers in patients with type 2 diabetes. J. Isfahan. Med. School. 30:2039–2051.
   Google Scholar